Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
British Journal of Cancer2024Vol. 130(6), pp. 941–950
Citations Over TimeTop 10% of 2024 papers
Shibani Nicum, Naomi McGregor, Rachel Austin, Linda Collins, Susan Dutton, Iain A. McNeish, Rosalind Glasspool, Marcia Hall, René L. Roux, Agnieszka Michael, Andrew R. Clamp, Gordon C. Jayson, Rebecca Kristeleit, Susana Banerjee, Anita Mansouri
Abstract
ISRCTN14784018, registered on 19th January 2018 http://www.isrctn.com/ISRCTN14784018 .
Related Papers
- → Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer(2021)88 cited
- → PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation(2018)48 cited
- → Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer(2019)31 cited
- → Olaparib-Resistant BRCA2MUT Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for Survival(2023)22 cited
- → Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2MUT ovarian cancer cells(2023)19 cited